New study aims to help fungal infection patients with damaged livers
NCT ID NCT07337720
First seen Jan 18, 2026 · Last updated May 15, 2026 · Updated 25 times
Summary
This study looks at how safe and effective the antifungal drug liposomal amphotericin B is for patients with a severe fungal infection called invasive aspergillosis who also have liver problems. About 40 adults in intensive care will receive the drug and be monitored for 6 weeks. The goal is to provide better treatment guidance for this high-risk group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASPERGILLOSIS INVASIVE are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.